Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 871 to 885 of 7707 results

  1. Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA968)

    NICE is unable to make a recommendation on melphalan flufenamide (Pepaxti) for treating relapsed or refractory multiple myeloma in adults. This is because Oncopeptides did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA968

  2. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA963)

    Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.

  3. Atogepant for preventing migraine (TA973)

    Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.

  4. Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)

    Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.

  5. Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (TA982)

    NICE is unable to make a recommendation about the use in the NHS of baricitinib (Olumiant) for treating juvenile idiopathic arthritis in people 2 years and over. This is because Eli Lilly did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA982

  6. Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)

    Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.

  7. Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)

    Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults.

  8. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

  9. Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)

    Evidence-based recommendations on tafamidis (Vyndaqel) for treating transthyretin amyloidosis with cardiomyopathy in adults.

  10. Reducing the risk of violent and aggressive behaviours

    A quick guide for registered managers of mental health services for young people

  11. Supporting people who provide unpaid care for adults with health or social care needs

    A quick guide for social care practitioners Good quality, consistent support helps the health, wellbeing and resilience of adult carers. Carers are...

  12. Understanding intermediate care, including reablement

    A guide to intermediate care services that provide support for a short time to help you recover and increase your independence

  13. What to expect during assessment and care planning

    A quick guide for people using adult social care services.

  14. Arranging services for people with a learning disability and behaviour that challenges

    A quick guide for commissioners People with a learning disability (or autism and a learning disability) and behaviour that challenges should have the

  15. Better home care for older people

    A quick and easy-to-read guide to the standard of care you should expect from a home care provider.